Optune Gio - Maxpoint Version 2.0
Novocure, GmbH · Decision date Oct 23, 2025
What did the FDA approve?
FDA records P100034/S041 as a supplement to PMA P100034, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 23, 2025.
FDA approval order statement
Approval for changes to the transducer array layout planning software MAXPOINT BR-I, including a trade name change to MAXPOINT.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- Oct 23, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P100034/S041
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- NZK
- Decision code
- APPR
- Decision date
- Oct 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, low electric field, tumor treatment.
- Applicant
- Novocure, GmbH
- Product code
- NZK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100034 · Original PMA
NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
P100034/S041 received
Application receipt date recorded by FDA.
P100034/S041 · FDA decision
Normal 180 Day Track
P100034/S043 · Related supplement
Optune Gio
P100034/S044 · Related supplement
Optune HFE Transducer Array Soft Part Components
P100034/S042 · Related supplement
Optune Gio
P100034/S046 · Related supplement
Optune HFE Transducer Arrays
P100034/S045 · Related supplement
Novocure GmbHs Optune Gio
Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Novocure, GmbH | PMA approval | Apr 8, 2011 | FDA | |
Optune GioP100034/S043 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune HFE Transducer Array Soft Part ComponentsP100034/S044 | Novocure, GmbH | PMA supplement | Apr 9, 2026 | FDA |
Optune GioP100034/S042 | Novocure, GmbH | PMA supplement | Jun 4, 2026 | FDA |
Optune HFE Transducer ArraysP100034/S046 | Novocure, GmbH | PMA supplement | Sep 16, 2026 | FDA |
Novocure GmbHs Optune GioP100034/S045 | Novocure, GmbH | PMA supplement | Sep 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P100034/S041
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




